Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Study shows beta blockers may benefit women with ovarian cancer

A new analysis of patient records indicates that certain drugs taken to improve heart health may also have anti-cancer properties.

25 Aug 2015

Veritas Genetics obtains CE mark approval for myBRCA genetic screening test

Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company's hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation Sequencing, in North America in May 2015.

25 Aug 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.

24 Aug 2015

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers.

24 Aug 2015

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.

23 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

New partnering scholarship launched to inspire and develop potential oncology nurses

As experienced oncology nurses know, a cancer diagnosis is only the first step on a long and challenging road ahead—for patients and providers alike. For both, a wide range of procedures becomes part and parcel of every day.

19 Aug 2015

TapImmune announces successful conveyance of Investigational New Drug Application from Mayo Clinic

TapImmune, Inc., a clinical stage immunotherapy company, specializing in the development of innovative technologies for the treatment of metastatic cancer, announced today the successful conveyance of the Mayo Clinic IND (Investigational New Drug Application) to TapImmune as part of the recently completed licensing agreement.

18 Aug 2015

New data assesses actionability of multigene panel testing for hereditary breast and ovarian cancer risk

Multigene testing of women negative for BRCA1 and BRCA2 found some of them harbored other harmful genetic mutations, most commonly moderate-risk breast and ovarian cancer genes and Lynch syndrome genes, which increase ovarian cancer risk, according to an article published online by JAMA Oncology.

14 Aug 2015

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.

14 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

USF Health, FORCE receive $1.45 million from PCORI to advance and expand clinical research network

A team led by the University of South Florida Morsani College of Medicine and the leading national hereditary breast and ovarian cancer advocacy organization, FORCE (Facing Our Risk of Cancer Empowered) received a $1.45-million funding award for a three-year project from the Patient-Centered Outcomes Research Institute to continue to advance and expand the ABOUT Network as part of the second phase of PCORnet: the National Patient-Centered Clinical Research Network.

13 Aug 2015

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

The University of New Mexico Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute's "NCI Comprehensive Cancer Center" designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico.

13 Aug 2015

UC Davis study finds higher survival rates for women diagnosed with ovarian cancer

Combing data collected on thousands of California ovarian cancer patients, UC Davis researchers have determined that almost one-third survived at least 10 years after diagnosis.

7 Aug 2015

Oral contraceptives give long-term protection against endometrial cancer, shows study

Use of oral contraceptives, even for just a few years, gives substantial long-term protection against endometrial cancer, and the longer the pill is used the greater the reduction in risk, according to a detailed re-analysis of all the available evidence, published in The Lancet Oncology journal.

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.

4 Aug 2015

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.

4 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Study shows beta blockers may benefit women with ovarian cancer

Veritas Genetics obtains CE mark approval for myBRCA genetic screening test

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Beta-blockers improve overall survival among epithelial ovarian cancer patients

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

New partnering scholarship launched to inspire and develop potential oncology nurses

TapImmune announces successful conveyance of Investigational New Drug Application from Mayo Clinic

New data assesses actionability of multigene panel testing for hereditary breast and ovarian cancer risk

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

USF Health, FORCE receive $1.45 million from PCORI to advance and expand clinical research network

UNMCC receives NCI Comprehensive Cancer Center designation for cancer treatment, research programs

UC Davis study finds higher survival rates for women diagnosed with ovarian cancer

Oral contraceptives give long-term protection against endometrial cancer, shows study

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Oasmia announces topline results from head-to-head comparison study of Paclical and Abraxane

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in